Related Experiment Videos
Growth retardation in children with chronic renal failure
1Department of Pediatrics, UCLA School of Medicine, Los Angeles, California 90095, USA.
Insights
Children with chronic renal failure (CRF) often experience growth retardation due to factors like malnutrition and hormonal imbalances. Understanding the role of parathyroid hormone-related protein (PTHrP) may reveal new therapeutic targets for improving linear growth in these patients.
Area of Science:
- Pediatric Nephrology
- Endocrinology
- Skeletal Biology
Background:
- Growth retardation is a significant challenge in pediatric chronic renal failure (CRF) management.
- Multiple factors contribute to impaired linear growth, including malnutrition, metabolic acidosis, growth hormone resistance, anemia, and renal osteodystrophy.
- Current therapies like growth hormone and calcitriol have limitations, and growth failure persists in many children with CRF.
Purpose of the Study:
- To explore the molecular mechanisms underlying growth failure in children with CRF.
- To investigate the role of parathyroid hormone-related protein (PTHrP) and its receptor in bone development in the context of CRF.
- To identify potential new therapeutic targets for improving linear growth in pediatric CRF.
Main Methods:
- Review of recent studies on growth regulation in CRF.
- Analysis of the role of PTH/PTHrP receptor in endochondral bone formation.
- Examination of PTH/PTHrP receptor mRNA expression in animal models of renal failure.
- Assessment of the impact of secondary hyperparathyroidism on growth plate morphology and chondrocyte markers.
Main Results:
- PTHrP and the PTH/PTHrP receptor are crucial for endochondral bone formation.
- PTH/PTHrP receptor mRNA expression is reduced in the kidneys and growth plate cartilage of animals with renal failure.
- Secondary hyperparathyroidism severity affects growth plate structure and chondrocyte differentiation markers in these animals.
Conclusions:
- Disrupted cartilage and bone development in CRF may be linked to molecular mechanisms involving the PTH/PTHrP pathway.
- These findings suggest potential targets for therapeutic interventions to improve linear growth in children with CRF.
- Further research into the PTH/PTHrP system could lead to optimized treatment strategies for growth failure in pediatric CRF.
Abstract:
Growth retardation is a major obstacle to full rehabilitation of children with chronic renal failure (CRF). Several factors have been identified as contributors to impaired linear growth and they include protein and calorie malnutrition, metabolic acidosis, growth hormone resistance, anemia, and renal osteodystrophy. Although therapeutic interventions such as the use of recombinant human growth hormone, recombinant human erythropoietin, and calcitriol have made substantial contributions, the optimal therapeutic strategy remains to be defined. Indeed, growth failure persists in a substantial proportion of children with renal failure and those treated with maintenance dialysis. In addition, the increasing prevalence of adynamic lesions of renal osteodystrophy and its effect on growth have raised concern about the continued generalized use of calcitriol in children with CRF. Recent studies have shown the critical roles of parathyroid hormone-related protein (PTHrP) and the PTH/PTHrP receptor in the regulation of endochondral bone formation. The PTH/PTHrP receptor mRNA expression has been shown to be down-regulated in kidney and growth plate cartilage of animals with renal failure. Differences in the severity of secondary hyperparathyroidism influence not only growth plate morphology but also the expression of selected markers of chondrocyte proliferation and differentiation in these animals. Such findings suggest potential molecular mechanisms by which cartilage and bone development may be disrupted in children with CRF, thereby contributing to diminished linear growth.